Jes Inda 'first-in-class' anti-tumor drugs launch global clinical trials!

On June 29, Vitrac Therapeutics, a subsidiary of Jetta, announced the launch of a global clinical trial of Aurora A kinase inhibitor VIC-1911VIC-1911 is a "first-in-class" anti-tumor drug developed by Taiho Pharmaceutical corporation in Japan (formerly known as TAS-119), Vitrac now owns the drug's exclusive global rights to development and commercialization in the field of oncology, where Jes Inda will be solely responsible for the development and commercialization of VIC-1911 in Greater ChinaAt present, the parties have completed VIC-1911 IND technical information and licensing the transfer of information to VitracFounded in 2010 in Zhangjiang, Shanghai,, the company is a company focused on the development of small molecules of original anti-cancer drugs, the company's founder and CEO is DrZhang JintaoPublic information shows that Jetinda uses its independent research and development and clinical products to introduce a "two-wheel drive" business model to accelerate the establishment of research and development pipelineVitrac is a subsidiary of Jes Inda in Boston, USA, responsible for project introduction and clinical developmentthis announcement of the launch of clinical trials, VIC-1911 is an Aurora A kinase inhibitor introduced from Taiho Corporation of JapanAurora kinase is a serine/sucone protease that regulates cell filament, with three subtypes, A, B and C, mainly acting on the central granules and spindles, which can maintain the normal process of cell divisionUnder normal circumstances, Aurora A is in the g2/M phase with silk split, affecting the central grain maturation, spindle body formation and other processesHowever, in tumor cells, Aurora A is expressed throughout the cycle of cell division, affecting the function of other proteins in the cell plasma, which eventually leads to the production of tumor cellscurrently, VIC-1911 has completed two Phase 1 clinical studies in the United States and EuropeThe combination of EGFR inhibitors such as VIC-1911 and Ochtinib is expected to improve the first-line treatment of non-small cell lung cancer of EGFR mutations, according to Phase 1a clinical trial data completed in the United StatesIt is reported that this year, the product will be in the United States for multiple indications of the 1b/2a phase 1b/2a clinical trialDrKeizo Koya, President of vitrac Therapeutics, , said, "We are proud to build on The Excellent work of Taiho to further develop aurora A kinase inhibitor VIC-1911 Aurora A kinase plays a key role in cancer-causing cell division, survival and proliferation, and we hope VIC-1911 will provide more treatment options for cancer patients "
it is worth mentioning that Jet inda has recently completed nearly RMB100 million of A-plus round financing, led by Juming Ventures, relying on Capital, Guofa Ventures, Zhidao Capital and Oriental Fuhai Heel Investment This round of financing is mainly used to promote the company's ERK kinase inhibitor JSI-1187 to conduct Phase 1 clinical trials, as well as to establish a new anti-tumor drug-centric research and development pipeline JSI-1187 is an oral small molecule extracellular signaling protein kinase 1/2 (ERK1/2) kinase inhibitor developed by Jas inda, which was approved by the FDA at the beginning of this year congratulates Jetta Aurora A kinase inhibitor VIC-1911 for launching a global clinical trial and hopes that this "first-in-class" anti-tumor will be successful in the research of the drug and will benefit patients as soon as possible! .